Myeloid-specific interleukin-6 response: from vascular effects to the potential for novel personalized medicines.
作者信息
Ketelhuth Daniel F J, Bäck Magnus
机构信息
CArdiovascularREsolution of INflammation to promote HEALTH (CARE-IN-HEALTH) Consortium.
Cardiovascular and Renal Research Unit, Department of Molecular Medicine, University of Southern Denmark, Campusvej 55, 5230 Odense, Denmark.
出版信息
Eur Heart J Open. 2024 Jun 12;4(4):oeae047. doi: 10.1093/ehjopen/oeae047. eCollection 2024 Jul.
Abstract
摘要
相似文献
1
Myeloid-specific interleukin-6 response: from vascular effects to the potential for novel personalized medicines.髓系特异性白细胞介素-6反应：从血管效应到新型个性化药物的潜力
Eur Heart J Open. 2024 Jun 12;4(4):oeae047. doi: 10.1093/ehjopen/oeae047. eCollection 2024 Jul.
2
Practicality of 3D Printed Personalized Medicines in Therapeutics.3D打印个性化药物在治疗中的实用性。
Front Pharmacol. 2021 Apr 12;12:646836. doi: 10.3389/fphar.2021.646836. eCollection 2021.
3
The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada.加拿大囊性纤维化个性化药物的公平实施
J Pers Med. 2021 May 7;11(5):382. doi: 10.3390/jpm11050382.
4
Myeloid cell-derived interleukin-6 induces vascular dysfunction and vascular and systemic inflammation.髓样细胞衍生的白细胞介素-6可诱导血管功能障碍以及血管和全身炎症。
Eur Heart J Open. 2024 Jun 12;4(4):oeae046. doi: 10.1093/ehjopen/oeae046. eCollection 2024 Jul.
5
Scenarios for 3D printing of personalized medicines - A case study.个性化药物3D打印方案——案例研究
Explor Res Clin Soc Pharm. 2021 Sep 25;4:100073. doi: 10.1016/j.rcsop.2021.100073. eCollection 2021 Dec.
6
Immunological efficacy of herbal medicines in prostate cancer patients treated by personalized peptide vaccine.个性化肽疫苗治疗前列腺癌患者中草药的免疫疗效。
Cancer Sci. 2017 Dec;108(12):2326-2332. doi: 10.1111/cas.13397. Epub 2017 Oct 3.
7
Development of Personalized Molecular Therapy for Acute Myeloid Leukemia.急性髓系白血病个性化分子疗法的发展
Curr Pharm Biotechnol. 2016;17(1):20-9. doi: 10.2174/1389201016666150930115024.
8
The Role of Metabolism in the Development of Personalized Therapies in Acute Myeloid Leukemia.代谢在急性髓系白血病个性化治疗发展中的作用
Front Oncol. 2021 May 19;11:665291. doi: 10.3389/fonc.2021.665291. eCollection 2021.
9
Anti-counterfeiting protection, personalized medicines - Development of 2D identification methods using laser technology.防伪保护、个性化药物——利用激光技术开发二维识别方法。
Int J Pharm. 2021 Aug 10;605:120793. doi: 10.1016/j.ijpharm.2021.120793. Epub 2021 Jun 10.
10
A novel eCIRP/TREM-1 pathway inhibitor attenuates acute kidney injury.一种新型的 eCIRP/TREM-1 通路抑制剂可减轻急性肾损伤。
Surgery. 2022 Aug;172(2):639-647. doi: 10.1016/j.surg.2022.02.003. Epub 2022 Mar 12.
引用本文的文献
1
Intervention, improved prevention, imaging, inflammation, and innovation: the five I's cardiovascular highlights in 2024.干预、强化预防、影像学、炎症与创新：2024年心血管领域五大亮点
Eur Heart J Open. 2025 Feb 28;5(1):oeaf015. doi: 10.1093/ehjopen/oeaf015. eCollection 2025 Jan.
本文引用的文献
1
Myeloid cell-derived interleukin-6 induces vascular dysfunction and vascular and systemic inflammation.髓样细胞衍生的白细胞介素-6可诱导血管功能障碍以及血管和全身炎症。
Eur Heart J Open. 2024 Jun 12;4(4):oeae046. doi: 10.1093/ehjopen/oeae046. eCollection 2024 Jul.
2
IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.接受维持性透析的患者中 clazakizumab 抑制白介素-6：一项随机 2b 期试验。
Nat Med. 2024 Aug;30(8):2328-2336. doi: 10.1038/s41591-024-03043-1. Epub 2024 May 25.
3
Obesity-induced inflammation exacerbates clonal hematopoiesis.肥胖引起的炎症会加重克隆性造血。
J Clin Invest. 2023 Jun 1;133(11):e163968. doi: 10.1172/JCI163968.
4
The role of inflammation and the possibilities of inflammation reduction to prevent cardiovascular events.炎症的作用以及减轻炎症以预防心血管事件的可能性。
Eur Heart J Open. 2022 Jun 14;2(4):oeac039. doi: 10.1093/ehjopen/oeac039. eCollection 2022 Jul.
5
TET2-Driven Clonal Hematopoiesis and Response to Canakinumab: An Exploratory Analysis of the CANTOS Randomized Clinical Trial.TET2 驱动的克隆性造血与卡那奴单抗反应：CANTOS 随机临床试验的探索性分析。
JAMA Cardiol. 2022 May 1;7(5):521-528. doi: 10.1001/jamacardio.2022.0386.
6
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial.在高动脉粥样硬化风险患者中使用 ziltivekimab 抑制白介素-6（RESCUE）：一项双盲、随机、安慰剂对照、2 期试验。
Lancet. 2021 May 29;397(10289):2060-2069. doi: 10.1016/S0140-6736(21)00520-1. Epub 2021 May 17.
Zotero 插件